Outbound Relationships |
Type |
Target |
Active |
Characteristic |
Refinability |
Group |
Values |
dexamethason 0,1 % wt/vol + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder suspension |
Is a |
Product containing neomycin (medicinal product) |
false |
Inferred relationship |
Some |
|
|
dexamethason 0,1 % wt/vol + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder suspension |
Is a |
Product containing dexamethasone (medicinal product) |
false |
Inferred relationship |
Some |
|
|
dexamethason 0,1 % wt/vol + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder suspension |
Is a |
antibiotikum til oftalmisk anvendelse |
false |
Inferred relationship |
Some |
|
|
dexamethason 0,1 % wt/vol + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder suspension |
Is a |
kombinationspræparater med neomycin |
false |
Inferred relationship |
Some |
|
|
dexamethason 0,1 % wt/vol + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder suspension |
Is a |
neomycin til topikal anvendelse |
false |
Inferred relationship |
Some |
|
|
dexamethason 0,1 % wt/vol + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder suspension |
Is a |
Product containing polymyxin B (medicinal product) |
false |
Inferred relationship |
Some |
|
|
dexamethason 0,1 % wt/vol + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Dexamethasone (substance) |
false |
Inferred relationship |
Some |
|
|
dexamethason 0,1 % wt/vol + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Polymyxin B (substance) |
false |
Inferred relationship |
Some |
|
|
dexamethason 0,1 % wt/vol + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
neomycin til topikal anvendelse |
false |
Inferred relationship |
Some |
|
|
dexamethason 0,1 % wt/vol + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder suspension |
Is a |
dexamethason + neomycinsulfat + polymyxin B-sulfat |
false |
Inferred relationship |
Some |
|
|
dexamethason 0,1 % wt/vol + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Neomycin sulfate |
false |
Inferred relationship |
Some |
|
|
dexamethason 0,1 % wt/vol + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Antiinfektiøst middel til huden |
false |
Inferred relationship |
Some |
|
|
dexamethason 0,1 % wt/vol + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Polymyxin B sulfate |
false |
Inferred relationship |
Some |
|
|
dexamethason 0,1 % wt/vol + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Corticosterone |
false |
Inferred relationship |
Some |
|
|
dexamethason 0,1 % wt/vol + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
binyrehormonmiddel |
false |
Inferred relationship |
Some |
|
|
dexamethason 0,1 % wt/vol + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Local anti-infective |
false |
Inferred relationship |
Some |
|
|
dexamethason 0,1 % wt/vol + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
glucocorticoidhormon |
false |
Inferred relationship |
Some |
|
|
dexamethason 0,1 % wt/vol + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
Baktericid |
false |
Inferred relationship |
Some |
|
|
dexamethason 0,1 % wt/vol + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder suspension |
Has manufactured dose form |
Ocular dose form (dose form) |
false |
Inferred relationship |
Some |
|
|
dexamethason 0,1 % wt/vol + neomycinsulfat 3,5 mg + polymyxin B-sulfat 10.000 enheder suspension |
Has manufactured dose form |
lægemiddelsuspension |
false |
Inferred relationship |
Some |
|
|